Rocket Pharmaceuticals, Inc. Finance Lease, Principal Payments
Rocket Pharmaceuticals, Inc. (RCKT) reported Finance Lease, Principal Payments of $948.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2026-06-30 was $474.00K, a 2.82% increase year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2026-03-31 was $474.00K, a 3.04% increase year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $471.00K, a 2.84% increase year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $464.00K, a 3.80% increase year-over-year.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2025 was $1.86M, a 3.63% increase from fiscal 2024.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2024 was $1.79M, a 38.19% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2023 was $1.30M, a 23.27% decline from fiscal 2022.
- Rocket Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2022 was $1.69M, a 2.74% increase from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month | Finance Lease, Principal Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $948.00K 10-Q · filed 2026-08-10 | $1.42M derived: sum of 3 quarters · filed 2026-08-10 | $1.88M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $474.00K 10-Q · filed 2026-05-07 | $945.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.41M derived: sum of 3 quarters · filed 2026-05-07 | $1.87M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $935.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.40M derived: sum of 3 quarters · filed 2026-08-10 | $1.86M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $925.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.39M 10-Q · filed 2025-11-06 | $1.84M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $921.00K 10-Q · filed 2026-08-10 | $1.38M derived: sum of 3 quarters · filed 2026-08-10 | $1.83M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $460.00K 10-Q · filed 2026-05-07 | $918.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.36M derived: sum of 3 quarters · filed 2026-05-07 | $1.81M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $905.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.35M derived: sum of 3 quarters · filed 2026-02-26 | $1.79M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $447.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $890.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.33M 10-Q · filed 2025-11-06 | $1.33M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $886.00K 10-Q · filed 2025-08-07 | $886.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.32M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $443.00K 10-Q · filed 2025-05-08 | $443.00K derived: sum of 2 quarters · filed 2025-05-08 | $877.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.31M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $434.00K derived: sum of 2 quarters · filed 2025-02-27 | $865.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.30M 10-K · filed 2025-02-27 | $1.74M 10-K · filed 2024-02-27 |
| 2023-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $865.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.30M 10-Q · filed 2024-11-07 | $1.72M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $862.00K 10-Q · filed 2024-08-06 | $1.29M derived: sum of 3 quarters · filed 2025-02-27 | $1.71M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $431.00K 10-Q · filed 2024-05-07 | $859.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.28M derived: sum of 3 quarters · filed 2025-02-27 | $1.70M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $850.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.27M derived: sum of 3 quarters · filed 2025-02-27 | $1.69M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $422.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $842.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.26M 10-Q · filed 2022-11-04 | $1.68M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $420.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $839.00K 10-Q · filed 2022-08-09 | $1.26M derived: sum of 3 quarters · filed 2024-02-27 | $1.67M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $419.00K 10-Q · filed 2022-05-06 | $836.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.25M derived: sum of 3 quarters · filed 2024-02-27 | $1.66M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $828.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.24M derived: sum of 3 quarters · filed 2024-02-27 | $1.64M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $819.00K derived: sum of 2 quarters · filed 2021-11-05 | $1.23M 10-Q · filed 2021-11-05 | $1.63M derived: sum of 4 quarters · filed 2021-11-05 | |
| 2021-06-30 | $408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $816.00K 10-Q · filed 2021-08-09 | $1.22M derived: sum of 3 quarters · filed 2021-08-09 | $1.62M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2021-03-31 | $408.00K 10-Q · filed 2021-05-10 | $813.00K derived: sum of 2 quarters · filed 2021-05-10 | $1.21M derived: sum of 3 quarters · filed 2021-05-10 | $1.48M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2020-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $805.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.07M derived: sum of 3 quarters · filed 2021-03-01 | $1.07M 10-K · filed 2021-03-01 | |
| 2020-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $665.00K derived: sum of 2 quarters · filed 2020-11-06 | $665.00K 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $265.00K 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |